MilliporeSigma Invests $286 Million in US Drug Safety Testing Capacity

Published on: 

The $286 million investment ability is designed to elevate MillioporeSigma’s ability to conduct biosafety testing and analytical development services.

MillporeSigma announced on Nov. 16, 2022 that its life science business sector is investing more than $286 million in its biosafety testing capacity at the company’s site in Rockville, Maryland. A new, state-of-the-art, 250,000 ft2 facility at the site will house biosafety testing, analytical development, viral clearance suites, and cell bank manufacturing services.

According to a company press release, the goal of this investment is to significantly increase the company’s ability to conduct biosafety testing and analytical development services. Over the next four years, the company expects the expansion to create more than 500 new jobs.

“MilliporeSigma is harnessing its broad portfolio of modern technologies and enabling services to help ensure the safety of the world’s medicines. These significant investments in Rockville and other sites across our global network will help us meet growing demand for the robust testing studies that biologics manufacturers depend upon to comply with stringent regulatory guidelines,” said Belén Garijo, chair of the executive board and CEO, Merck KGaA, Darmstadt, Germany, in the release. “This is a prime example of our focus on sustainable growth in areas with strong underlying upwards dynamics.”


“This is the largest investment in contract testing in Merck KGaA, Darmstadt, Germany’s history,” said Matthias Heinzel, member of the executive board, Merck KGaA, Darmstadt, Germany, and CEO, Life Science. “We thank the State of Maryland and Montgomery County, Maryland, for their collaboration in making this new campus a reality for our employees and clients. Together, we are impacting life and health with science.”

Source: MilliporeSigma